Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin
Background We investigated early tumor shrinkage (ETS) and depth of response (DpR) using data from the G-SOX study comparing S-1 plus oxaliplatin with S-1 plus cisplatin as the first-line treatment for advanced gastric cancer (AGC). Methods ETS was determined as % decrease in the sum of the longest...
Gespeichert in:
| Veröffentlicht in: | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2019-01, Vol.22 (1), p.138-146 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | 1 |
| container_start_page | 138 |
| container_title | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association |
| container_volume | 22 |
| creator | Nishina, Tomohiro Azuma, Mizutomo Nishikawa, Kazuhiro Gotoh, Masahiro Bando, Hideaki Sugimoto, Naotoshi Amagai, Kenji Chin, Keisho Niwa, Yasumasa Tsuji, Akihito Imamura, Hiroshi Tsuda, Masahiro Yasui, Hirofumi Fujii, Hirofumi Yamaguchi, Kensei Yasui, Hisateru Hironaka, Shuichi Shimada, Ken Miwa, Hiroto Mitome, Terukazu Kageyama, Hiroki Hyodo, Ichinosuke |
| description | Background
We investigated early tumor shrinkage (ETS) and depth of response (DpR) using data from the G-SOX study comparing S-1 plus oxaliplatin with S-1 plus cisplatin as the first-line treatment for advanced gastric cancer (AGC).
Methods
ETS was determined as % decrease in the sum of the longest diameters of the target lesions at the first evaluation of week 6 compared to baseline. DpR was the maximum % shrinkage during the study treatment. The impact of ETS (cutoff value 20%) and DpR (continuous value) on progression-free survival (PFS) and overall survival (OS) were assessed by the log-rank test and Cox regression analysis including prognostic factors obtained in the G-SOX study; ECOG performance status, baseline sum of tumor diameters, disease status (recurrent/unresectable), and histology (diffuse/intestinal).
Results
Among 685 patients enrolled in the G-SOX study, 632 patients who had the first tumor evaluation were analyzed. Patients with ETS ≥ 20% had longer PFS (median 4.5 vs. 2.8 months,
p
|
| doi_str_mv | 10.1007/s10120-018-0845-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2060866993</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2060866993</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-8779af953743df3ab287c17f4f125b11e6df4c4a5c541a3adcd9c4338e6557933</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhSMEoqXwAGyQJTZsUuz4L2GHqhZGqsQCWEd3bGfGJXGCrzMwPGEfC4e0VEJi5Z9zznele4riJaPnjFL9FhllFS0pq0taC1nqR8UpE1yVnFP5-P5eNeykeIZ4QymTDVNPi5OqaUTNa3Va3F5C7I8kzcMYCe6jD99g5wgES6yb0p6MHYkOpzGgIz6QCZJ3ISH54bMI9gDBOEt2gCl6Q8zyjO8I5FCKI07OJH9YeNAf0eOCy1rGj4P_lYPTHjJ4s9kQTLM9LnrnI6ay98GRzyUjUz_n2E_o_dTn4YEc8PxBMB7X7-fFkw56dC_uzrPi69Xll4uP5fWnD5uL99elEUymsta6ga6RXAtuOw7bqtaG6U50rJJbxpyynTACpJGCAQdrbGME57VTUuqG87Pizcqd4vh9dpjawaNxfQ_BjTO2FVW0Vqr5Y339j_VmnGPexOKSlRKCC5VdbHWZvC-Mrmun6AeIx5bRdqm5XWtuc83tUnOrc-bVHXneDs7-Tdz3mg3VasAshZ2LD6P_T_0Nmze1Dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2052644346</pqid></control><display><type>article</type><title>Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nishina, Tomohiro ; Azuma, Mizutomo ; Nishikawa, Kazuhiro ; Gotoh, Masahiro ; Bando, Hideaki ; Sugimoto, Naotoshi ; Amagai, Kenji ; Chin, Keisho ; Niwa, Yasumasa ; Tsuji, Akihito ; Imamura, Hiroshi ; Tsuda, Masahiro ; Yasui, Hirofumi ; Fujii, Hirofumi ; Yamaguchi, Kensei ; Yasui, Hisateru ; Hironaka, Shuichi ; Shimada, Ken ; Miwa, Hiroto ; Mitome, Terukazu ; Kageyama, Hiroki ; Hyodo, Ichinosuke</creator><creatorcontrib>Nishina, Tomohiro ; Azuma, Mizutomo ; Nishikawa, Kazuhiro ; Gotoh, Masahiro ; Bando, Hideaki ; Sugimoto, Naotoshi ; Amagai, Kenji ; Chin, Keisho ; Niwa, Yasumasa ; Tsuji, Akihito ; Imamura, Hiroshi ; Tsuda, Masahiro ; Yasui, Hirofumi ; Fujii, Hirofumi ; Yamaguchi, Kensei ; Yasui, Hisateru ; Hironaka, Shuichi ; Shimada, Ken ; Miwa, Hiroto ; Mitome, Terukazu ; Kageyama, Hiroki ; Hyodo, Ichinosuke</creatorcontrib><description>Background
We investigated early tumor shrinkage (ETS) and depth of response (DpR) using data from the G-SOX study comparing S-1 plus oxaliplatin with S-1 plus cisplatin as the first-line treatment for advanced gastric cancer (AGC).
Methods
ETS was determined as % decrease in the sum of the longest diameters of the target lesions at the first evaluation of week 6 compared to baseline. DpR was the maximum % shrinkage during the study treatment. The impact of ETS (cutoff value 20%) and DpR (continuous value) on progression-free survival (PFS) and overall survival (OS) were assessed by the log-rank test and Cox regression analysis including prognostic factors obtained in the G-SOX study; ECOG performance status, baseline sum of tumor diameters, disease status (recurrent/unresectable), and histology (diffuse/intestinal).
Results
Among 685 patients enrolled in the G-SOX study, 632 patients who had the first tumor evaluation were analyzed. Patients with ETS ≥ 20% had longer PFS (median 4.5 vs. 2.8 months,
p
< 0.0001) and OS (median 14.8 vs. 10.5 months,
p
< 0.0001) than those with ETS < 20%. Adjusted hazard ratios of ETS < 20 vs. ≥ 20% were 0.606 (95% confidence interval (CI) 0.506–0.725) for PFS and 0.589 (95% CI 0.492–0.704) for OS. DpR was also significantly associated with PFS and OS (both
p
< 0.0001). These results were similar between the SOX and CS groups.
Conclusions
In AGC patients receiving the first-line therapy, ETS and DpR might be predictors for PFS and OS.</description><identifier>ISSN: 1436-3291</identifier><identifier>EISSN: 1436-3305</identifier><identifier>DOI: 10.1007/s10120-018-0845-7</identifier><identifier>PMID: 29948386</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Abdominal Surgery ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer Research ; Chemotherapy ; Cisplatin ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Clinical Trials, Phase III as Topic ; Drug Combinations ; Female ; Gastric cancer ; Gastroenterology ; Histology ; Humans ; Intestine ; Kaplan-Meier Estimate ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Multicenter Studies as Topic ; Oncology ; Original Article ; Oxaliplatin ; Oxaliplatin - administration & dosage ; Oxaliplatin - adverse effects ; Oxonic Acid - administration & dosage ; Oxonic Acid - adverse effects ; Patients ; Progression-Free Survival ; Proportional Hazards Models ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - mortality ; Surgical Oncology ; Survival ; Tegafur - administration & dosage ; Tegafur - adverse effects ; Young Adult</subject><ispartof>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-01, Vol.22 (1), p.138-146</ispartof><rights>The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018</rights><rights>Gastric Cancer is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-8779af953743df3ab287c17f4f125b11e6df4c4a5c541a3adcd9c4338e6557933</citedby><cites>FETCH-LOGICAL-c415t-8779af953743df3ab287c17f4f125b11e6df4c4a5c541a3adcd9c4338e6557933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10120-018-0845-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10120-018-0845-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29948386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishina, Tomohiro</creatorcontrib><creatorcontrib>Azuma, Mizutomo</creatorcontrib><creatorcontrib>Nishikawa, Kazuhiro</creatorcontrib><creatorcontrib>Gotoh, Masahiro</creatorcontrib><creatorcontrib>Bando, Hideaki</creatorcontrib><creatorcontrib>Sugimoto, Naotoshi</creatorcontrib><creatorcontrib>Amagai, Kenji</creatorcontrib><creatorcontrib>Chin, Keisho</creatorcontrib><creatorcontrib>Niwa, Yasumasa</creatorcontrib><creatorcontrib>Tsuji, Akihito</creatorcontrib><creatorcontrib>Imamura, Hiroshi</creatorcontrib><creatorcontrib>Tsuda, Masahiro</creatorcontrib><creatorcontrib>Yasui, Hirofumi</creatorcontrib><creatorcontrib>Fujii, Hirofumi</creatorcontrib><creatorcontrib>Yamaguchi, Kensei</creatorcontrib><creatorcontrib>Yasui, Hisateru</creatorcontrib><creatorcontrib>Hironaka, Shuichi</creatorcontrib><creatorcontrib>Shimada, Ken</creatorcontrib><creatorcontrib>Miwa, Hiroto</creatorcontrib><creatorcontrib>Mitome, Terukazu</creatorcontrib><creatorcontrib>Kageyama, Hiroki</creatorcontrib><creatorcontrib>Hyodo, Ichinosuke</creatorcontrib><title>Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin</title><title>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</title><addtitle>Gastric Cancer</addtitle><addtitle>Gastric Cancer</addtitle><description>Background
We investigated early tumor shrinkage (ETS) and depth of response (DpR) using data from the G-SOX study comparing S-1 plus oxaliplatin with S-1 plus cisplatin as the first-line treatment for advanced gastric cancer (AGC).
Methods
ETS was determined as % decrease in the sum of the longest diameters of the target lesions at the first evaluation of week 6 compared to baseline. DpR was the maximum % shrinkage during the study treatment. The impact of ETS (cutoff value 20%) and DpR (continuous value) on progression-free survival (PFS) and overall survival (OS) were assessed by the log-rank test and Cox regression analysis including prognostic factors obtained in the G-SOX study; ECOG performance status, baseline sum of tumor diameters, disease status (recurrent/unresectable), and histology (diffuse/intestinal).
Results
Among 685 patients enrolled in the G-SOX study, 632 patients who had the first tumor evaluation were analyzed. Patients with ETS ≥ 20% had longer PFS (median 4.5 vs. 2.8 months,
p
< 0.0001) and OS (median 14.8 vs. 10.5 months,
p
< 0.0001) than those with ETS < 20%. Adjusted hazard ratios of ETS < 20 vs. ≥ 20% were 0.606 (95% confidence interval (CI) 0.506–0.725) for PFS and 0.589 (95% CI 0.492–0.704) for OS. DpR was also significantly associated with PFS and OS (both
p
< 0.0001). These results were similar between the SOX and CS groups.
Conclusions
In AGC patients receiving the first-line therapy, ETS and DpR might be predictors for PFS and OS.</description><subject>Abdominal Surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>Gastroenterology</subject><subject>Histology</subject><subject>Humans</subject><subject>Intestine</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Oxaliplatin</subject><subject>Oxaliplatin - administration & dosage</subject><subject>Oxaliplatin - adverse effects</subject><subject>Oxonic Acid - administration & dosage</subject><subject>Oxonic Acid - adverse effects</subject><subject>Patients</subject><subject>Progression-Free Survival</subject><subject>Proportional Hazards Models</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Retrospective Studies</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - mortality</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Tegafur - administration & dosage</subject><subject>Tegafur - adverse effects</subject><subject>Young Adult</subject><issn>1436-3291</issn><issn>1436-3305</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1u1DAUhSMEoqXwAGyQJTZsUuz4L2GHqhZGqsQCWEd3bGfGJXGCrzMwPGEfC4e0VEJi5Z9zznele4riJaPnjFL9FhllFS0pq0taC1nqR8UpE1yVnFP5-P5eNeykeIZ4QymTDVNPi5OqaUTNa3Va3F5C7I8kzcMYCe6jD99g5wgES6yb0p6MHYkOpzGgIz6QCZJ3ISH54bMI9gDBOEt2gCl6Q8zyjO8I5FCKI07OJH9YeNAf0eOCy1rGj4P_lYPTHjJ4s9kQTLM9LnrnI6ay98GRzyUjUz_n2E_o_dTn4YEc8PxBMB7X7-fFkw56dC_uzrPi69Xll4uP5fWnD5uL99elEUymsta6ga6RXAtuOw7bqtaG6U50rJJbxpyynTACpJGCAQdrbGME57VTUuqG87Pizcqd4vh9dpjawaNxfQ_BjTO2FVW0Vqr5Y339j_VmnGPexOKSlRKCC5VdbHWZvC-Mrmun6AeIx5bRdqm5XWtuc83tUnOrc-bVHXneDs7-Tdz3mg3VasAshZ2LD6P_T_0Nmze1Dw</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Nishina, Tomohiro</creator><creator>Azuma, Mizutomo</creator><creator>Nishikawa, Kazuhiro</creator><creator>Gotoh, Masahiro</creator><creator>Bando, Hideaki</creator><creator>Sugimoto, Naotoshi</creator><creator>Amagai, Kenji</creator><creator>Chin, Keisho</creator><creator>Niwa, Yasumasa</creator><creator>Tsuji, Akihito</creator><creator>Imamura, Hiroshi</creator><creator>Tsuda, Masahiro</creator><creator>Yasui, Hirofumi</creator><creator>Fujii, Hirofumi</creator><creator>Yamaguchi, Kensei</creator><creator>Yasui, Hisateru</creator><creator>Hironaka, Shuichi</creator><creator>Shimada, Ken</creator><creator>Miwa, Hiroto</creator><creator>Mitome, Terukazu</creator><creator>Kageyama, Hiroki</creator><creator>Hyodo, Ichinosuke</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190101</creationdate><title>Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin</title><author>Nishina, Tomohiro ; Azuma, Mizutomo ; Nishikawa, Kazuhiro ; Gotoh, Masahiro ; Bando, Hideaki ; Sugimoto, Naotoshi ; Amagai, Kenji ; Chin, Keisho ; Niwa, Yasumasa ; Tsuji, Akihito ; Imamura, Hiroshi ; Tsuda, Masahiro ; Yasui, Hirofumi ; Fujii, Hirofumi ; Yamaguchi, Kensei ; Yasui, Hisateru ; Hironaka, Shuichi ; Shimada, Ken ; Miwa, Hiroto ; Mitome, Terukazu ; Kageyama, Hiroki ; Hyodo, Ichinosuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-8779af953743df3ab287c17f4f125b11e6df4c4a5c541a3adcd9c4338e6557933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Abdominal Surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>Gastroenterology</topic><topic>Histology</topic><topic>Humans</topic><topic>Intestine</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Oxaliplatin</topic><topic>Oxaliplatin - administration & dosage</topic><topic>Oxaliplatin - adverse effects</topic><topic>Oxonic Acid - administration & dosage</topic><topic>Oxonic Acid - adverse effects</topic><topic>Patients</topic><topic>Progression-Free Survival</topic><topic>Proportional Hazards Models</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Retrospective Studies</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - mortality</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Tegafur - administration & dosage</topic><topic>Tegafur - adverse effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishina, Tomohiro</creatorcontrib><creatorcontrib>Azuma, Mizutomo</creatorcontrib><creatorcontrib>Nishikawa, Kazuhiro</creatorcontrib><creatorcontrib>Gotoh, Masahiro</creatorcontrib><creatorcontrib>Bando, Hideaki</creatorcontrib><creatorcontrib>Sugimoto, Naotoshi</creatorcontrib><creatorcontrib>Amagai, Kenji</creatorcontrib><creatorcontrib>Chin, Keisho</creatorcontrib><creatorcontrib>Niwa, Yasumasa</creatorcontrib><creatorcontrib>Tsuji, Akihito</creatorcontrib><creatorcontrib>Imamura, Hiroshi</creatorcontrib><creatorcontrib>Tsuda, Masahiro</creatorcontrib><creatorcontrib>Yasui, Hirofumi</creatorcontrib><creatorcontrib>Fujii, Hirofumi</creatorcontrib><creatorcontrib>Yamaguchi, Kensei</creatorcontrib><creatorcontrib>Yasui, Hisateru</creatorcontrib><creatorcontrib>Hironaka, Shuichi</creatorcontrib><creatorcontrib>Shimada, Ken</creatorcontrib><creatorcontrib>Miwa, Hiroto</creatorcontrib><creatorcontrib>Mitome, Terukazu</creatorcontrib><creatorcontrib>Kageyama, Hiroki</creatorcontrib><creatorcontrib>Hyodo, Ichinosuke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishina, Tomohiro</au><au>Azuma, Mizutomo</au><au>Nishikawa, Kazuhiro</au><au>Gotoh, Masahiro</au><au>Bando, Hideaki</au><au>Sugimoto, Naotoshi</au><au>Amagai, Kenji</au><au>Chin, Keisho</au><au>Niwa, Yasumasa</au><au>Tsuji, Akihito</au><au>Imamura, Hiroshi</au><au>Tsuda, Masahiro</au><au>Yasui, Hirofumi</au><au>Fujii, Hirofumi</au><au>Yamaguchi, Kensei</au><au>Yasui, Hisateru</au><au>Hironaka, Shuichi</au><au>Shimada, Ken</au><au>Miwa, Hiroto</au><au>Mitome, Terukazu</au><au>Kageyama, Hiroki</au><au>Hyodo, Ichinosuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin</atitle><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle><stitle>Gastric Cancer</stitle><addtitle>Gastric Cancer</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>22</volume><issue>1</issue><spage>138</spage><epage>146</epage><pages>138-146</pages><issn>1436-3291</issn><eissn>1436-3305</eissn><abstract>Background
We investigated early tumor shrinkage (ETS) and depth of response (DpR) using data from the G-SOX study comparing S-1 plus oxaliplatin with S-1 plus cisplatin as the first-line treatment for advanced gastric cancer (AGC).
Methods
ETS was determined as % decrease in the sum of the longest diameters of the target lesions at the first evaluation of week 6 compared to baseline. DpR was the maximum % shrinkage during the study treatment. The impact of ETS (cutoff value 20%) and DpR (continuous value) on progression-free survival (PFS) and overall survival (OS) were assessed by the log-rank test and Cox regression analysis including prognostic factors obtained in the G-SOX study; ECOG performance status, baseline sum of tumor diameters, disease status (recurrent/unresectable), and histology (diffuse/intestinal).
Results
Among 685 patients enrolled in the G-SOX study, 632 patients who had the first tumor evaluation were analyzed. Patients with ETS ≥ 20% had longer PFS (median 4.5 vs. 2.8 months,
p
< 0.0001) and OS (median 14.8 vs. 10.5 months,
p
< 0.0001) than those with ETS < 20%. Adjusted hazard ratios of ETS < 20 vs. ≥ 20% were 0.606 (95% confidence interval (CI) 0.506–0.725) for PFS and 0.589 (95% CI 0.492–0.704) for OS. DpR was also significantly associated with PFS and OS (both
p
< 0.0001). These results were similar between the SOX and CS groups.
Conclusions
In AGC patients receiving the first-line therapy, ETS and DpR might be predictors for PFS and OS.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>29948386</pmid><doi>10.1007/s10120-018-0845-7</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1436-3291 |
| ispartof | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-01, Vol.22 (1), p.138-146 |
| issn | 1436-3291 1436-3305 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2060866993 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | Abdominal Surgery Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Chemotherapy Cisplatin Cisplatin - administration & dosage Cisplatin - adverse effects Clinical Trials, Phase III as Topic Drug Combinations Female Gastric cancer Gastroenterology Histology Humans Intestine Kaplan-Meier Estimate Male Medical prognosis Medicine Medicine & Public Health Middle Aged Multicenter Studies as Topic Oncology Original Article Oxaliplatin Oxaliplatin - administration & dosage Oxaliplatin - adverse effects Oxonic Acid - administration & dosage Oxonic Acid - adverse effects Patients Progression-Free Survival Proportional Hazards Models Randomized Controlled Trials as Topic Retrospective Studies Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Surgical Oncology Survival Tegafur - administration & dosage Tegafur - adverse effects Young Adult |
| title | Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A07%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20tumor%20shrinkage%20and%20depth%20of%20response%20in%20patients%20with%20advanced%20gastric%20cancer:%20a%20retrospective%20analysis%20of%20a%20randomized%20phase%20III%20study%20of%20first-line%20S-1%20plus%20oxaliplatin%20vs.%20S-1%20plus%20cisplatin&rft.jtitle=Gastric%20cancer%20:%20official%20journal%20of%20the%20International%20Gastric%20Cancer%20Association%20and%20the%20Japanese%20Gastric%20Cancer%20Association&rft.au=Nishina,%20Tomohiro&rft.date=2019-01-01&rft.volume=22&rft.issue=1&rft.spage=138&rft.epage=146&rft.pages=138-146&rft.issn=1436-3291&rft.eissn=1436-3305&rft_id=info:doi/10.1007/s10120-018-0845-7&rft_dat=%3Cproquest_cross%3E2060866993%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2052644346&rft_id=info:pmid/29948386&rfr_iscdi=true |